{"nctId":"NCT00968708","briefTitle":"Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome","startDateStruct":{"date":"2009-09"},"conditions":["Diabetes Mellitus, Type 2","Acute Coronary Syndrome"],"count":5380,"armGroups":[{"label":"Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo"]},{"label":"Alogliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Alogliptin"]}],"interventions":[{"name":"Alogliptin","otherNames":["NesinaÂ®","SYR-322","SYR110322"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of type 2 diabetes mellitus\n* Is receiving monotherapy or combination antidiabetic therapy with a glycosylated hemoglobin level between 6.5% and 11.0%, inclusive, at Screening (between 7.0 and 11.0%, inclusive, if the participant's antidiabetic regimen includes insulin)\n* Diagnosis of acute coronary syndrome within 15 to 90 days prior to randomization.\n\nExclusion Criteria:\n\n* Signs of type 1 diabetes mellitus\n* Currently receiving a glucagon-like peptide-1 analogue for glycemic control of type 2 diabetes mellitus at Screening\n* Received a dipeptidyl peptidase-4 inhibitor for either more than 14 days total or within the 3 months prior to Screening.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Primary Major Adverse Cardiac Events (MACE)","description":"Primary Major Adverse Cardiac Events were defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"11.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Secondary Major Adverse Cardiac Events (MACE)","description":"Secondary MACE composite consisted of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent revascularization due to unstable angina; these events were adjudicated by an independent cardiovascular endpoint committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null},{"groupId":"OG001","value":"12.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":952,"n":2679},"commonTop":["Hypertension","Renal impairment","Hypoglycaemia","Blood creatine phosphokinase increased","Angina pectoris"]}}}